课题基金 / 基金详情

PS16-003, Evaluation of TransLife Center: A Locally-Developed Combination Prevention Intervention for Transgender Women at High Risk of HIV Infection

PS16-003, Evaluation of TransLife Center: A Locally-Developed Combination Prevention Intervention for Transgender Women at High Risk of HIV Infection
PS16-003,TransLife 中心评估:针对艾滋病毒感染高危跨性别女性的本地开发的联合预防干预措施
批准号:
9753066
负责人:
Lisa Mary Kuhns
金额:
$40.0万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-30 至 2020-09-29

项目摘要

项目成果

Lisa Mary Kuhns的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Combination interventions to reduce disparities in HIV infection for transgender women (TW) who have sex with men are sorely needed, as this population is one of the highest risk and most underserved groups in the United States. The goal of this proposed research project is to evaluate a locally developed and potentially effective intervention, the TransLife Center (TLC), which provides combination (i.e., biomedical, behavioral, social/structural) HIV prevention services to adult TW at high risk for HIV infection, in a culturally specific and highly accessible affirming environment. The TLC intervention directly addresses the structural barriers to health promotion among TW through a coordinated screening and service model, including direct access to services most needed and requested by TW: employment, housing, legal, and health services, following a social determinants of health conceptual model. To date there are no evidence-based HIV prevention interventions (EBIs) for TW listed in the CDC compendium of EBIs. The proposed study will address this gap through collaboration between Chicago House and Social Service Agency (Chicago House), a long-standing HIV/AIDS service provider and HIV prevention researchers who have been actively engaged in the development of HIV prevention interventions for TW. Our experience suggests that Chicago House's TLC intervention is feasible and acceptable to the target population, with over 200 HIV-uninfected TW participating in services over the past three years and evidence suggesting potential efficacy of the intervention for both sexual risk reduction and health promotion. We propose to test the TLC intervention in a single arm trial among 100 HIV-uninfected and sexually active TW, ages 18 and older, and evaluate intervention effectiveness over a 12-month period with visits at 6-month intervals (baseline, 6-months, 12-months). All participants will receive standard-of-care HIV/STI prevention and testing services, assessment and linkage to pre-exposure prophylaxis (PrEP), as indicated. We will evaluate the TLC intervention via the following aims: AIM 1) To determine the pre-post efficacy of the TLC intervention on the primary outcome: number of condomless anal sex acts without protection by PrEP. 1a) To assess the dose response relationship between intervention exposure as well as exposure to specific components (i.e., employment, housing, legal, and health) on reductions in the primary outcome. 1b) To assess mediation of intervention effects on protective processes (gender affirmation, collective self-esteem, social support) theorized to increase with intervention exposure; AIM 2) To examine intervention implementation experiences through semi-structured interviews with 20 TLC participants and 10 Chicago House staff members. AIM 3) Exploratory Aims: 3a) To describe the trajectory of PrEP indication, uptake, retention and adherence in the community-based sample over a 12-month follow-up period and evaluate the impact of the TLC intervention on the PrEP continuum of care. 3b) To explore whether reductions in HIV risk are associated with epidemiologically-linked moderators including age and race/ethnicity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mobile Adaptation and Testing of a Uniquely Targeted HIV Intervention for Young Transgender Women
  • 批准号:
    9765545
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2018
  • 负责人:
    Lisa Mary Kuhns
  • 依托单位:
国内基金
海外基金
SRSF3抑制剂SFI003逆转急性髓系白血病耐药性的功能与机制研究
  • 批准号:
    2026JJ60275
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    邢程
  • 依托单位:
新型溶瘤性HPV治疗性疫苗MATV003的构建和药效学研究
  • 批准号:
    JCZRMS202601746
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
基于JAK-STAT信号通路研究E003调控URSA的Th17/Treg免疫平衡的分子机制
  • 批准号:
    82360318
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    31.00万元
  • 批准年份:
    2023
  • 负责人:
    章志琴
  • 依托单位:
噬菌体PaoP5编码蛋白Orf003通过FleQ抑制铜绿假单胞菌运动的分子机制研究